Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EVO756

Small molecule · developed by Evommune

Phase 2 Most advanced trial

EVMN Developer

3 Registered trials

What is EVO756?

EVO756 is an orally administered agent studied in migraine, chronic inducible urticaria and atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Dermatology, Immunology, Neurology
Developer: Evommune, Inc. (EVMN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07616128	Phase 2	Migraine	Recruiting	EVMN
NCT07150845	Phase 2	Atopic Dermatitis	Completed	EVMN
NCT06603220	Phase 2	Chronic Inducible Urticaria	Completed	EVMN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MigraineAtopic DermatitisChronic Inducible Urticaria

More from Evommune

EVO101 Phase 2 EVO301 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the EVMN page.

Follow EVMN, the company behind EVO756

See EVMN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVMN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z